Series A Financing and Financial Structure

Latus Bio, Inc. has completed a $97 million Series A financing. This includes an initial $54 million in 2024 and a subsequent $43 million extension led by 8VC, with participation from Korea Development Bank (KDB). Securing substantial funding in a challenging venture capital environment demonstrates recognition of the value of Latus Bio's innovative adeno-associated virus (AAV) capsid platform technology.

Enhanced Safety and Efficacy through Low-Dose Targeted Delivery

Latus Bio is leveraging a low-dose delivery platform to address the limitations of existing gene therapies, particularly the adverse effects associated with high-dose administration. Their proprietary engineered capsids, AAV-DB-3 and AAV-Ep+, are designed to precisely deliver therapeutic genes to target brain tissues. This approach significantly reduces the risk of liver toxicity and systemic immune responses, while also lowering production costs, potentially leading to a competitive pricing advantage upon commercialization.

LTS-201 and MSH3 Inhibition for Huntington's Disease Treatment

LTS-201, the company's lead pipeline asset, is an innovative gene therapy candidate for Huntington's Disease. Unlike competitors that directly inhibit Huntingtin (HTT) protein expression, LTS-201 employs a novel mechanism by targeting and inhibiting MSH3, a DNA repair enzyme that promotes the expansion of CAG repeat sequences. The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the third quarter of 2026, offering a new therapeutic approach to address the underlying cause of the disease.

LTS-101 Enters Clinical Trials and Targets Ultra-Rare Disease Market

LTS-101, another key asset, is a gene therapy candidate for CLN2-type Batten Disease, an ultra-rare neurological disorder. This therapy has received FDA Fast Track and Orphan Drug designations and has completed IND approval, paving the way for entry into a researcher-initiated clinical trial (IIT) in the third quarter of 2026. Compared to BioMarin's Brineura, a high-cost enzyme replacement therapy, LTS-101 aims to provide a single-dose treatment that delivers the missing TPP1 enzyme to the entire brain, potentially maximizing patient convenience.

Platform Diversification and Long-Term Partnership Prospects

With the newly secured funding, Latus Bio plans to rapidly generate safety and efficacy data for its early-stage pipeline assets, demonstrating the versatility of its platform. If their low-dose CNS delivery technology proves effective in human clinical trials, it could facilitate expansion into other neurological disorders with larger patient populations, such as Alzheimer's Disease. This would position the company for potential large-scale licensing agreements with global pharmaceutical companies, creating a strong foundation for future growth.